99mTc-HMPAO as a tumour blood flow agent. Academic Article uri icon

Overview

abstract

  • The cerebral blood flow agent, 99mTc-HMPAO ('CeretecTM') has been investigated to see if it can be used to estimate tumour blood flow. Its distribution in Balb/c mice bearing either a subcutaneously implanted sarcoma or a plasmacytoma has been shown to be similar to that of 86RbCl. The changes in peripheral blood flow caused by the beta-blocker, propranolol, and by Nembutal anaesthesia, are manifested equally by 99mTc-HMPAO and 86Rb. We conclude, therefore, that HMPAO may be useful in estimating tumour perfusion.

publication date

  • January 1, 1987

Research

keywords

  • Neoplasms, Experimental
  • Organometallic Compounds
  • Oximes

Identity

Scopus Document Identifier

  • 0023160007

Digital Object Identifier (DOI)

  • 10.1007/BF00256023

PubMed ID

  • 3609059

Additional Document Info

volume

  • 13

issue

  • 2